Drug Trial Radar · NCT03025789
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
174
Actual
Start
Nov 10, 2016
Primary completion
Feb 1, 2021
Study completion Feb 1, 2021
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi
- First posted
- Jan 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the effectiveness of fexinidazole administered to patients with human African trypanosomiasis due to T. b. gambiense (g-HAT) at all stages of the disease. The aim of the present study is to provide additional information on the effectiveness and safety of fexinidazole and to assess its use under conditions as close as possible to those in real life, both in patients treated on an out-patient basis and in the hospital setting, depending on clinical status. Participants will receive fexinidazole oral treatment for 10 days. Regular blood draws and lumbar punctures will be performed over 18 months to confirm the cure of the disease. Other assessments will include the recording of adverse events, signs and symptoms of the disease, laboratory tests, vital signs, electrocardiograms. Treatment compliance, feasibility, and packaging acceptability will be thoroughly assessed in the participants receiving treatment at home. Those participants will complete questionnaires to check that instructions for fexinidazole administration are clear enough and followed correctly.
Conditions
- Trypanosomiasis, African
- Sleeping Sickness
- Trypanosomiasis; Gambian
Interventions
FexinidazoleDrug
Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Whose Treatment Outcome at Month 18 is a SuccessTime frame: Between the first intake of fexinidazole (Day 1) and the end of the follow-up period (18 months)
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Roi Baudouin Hospital
Kinshasa, Democratic Republic of the Congo
Dipumba Hospital
Mbuji-Mayi, Kasaï Oriental Province, Democratic Republic of the Congo
Bagata Hospital
Bagata, Kwilu, Democratic Republic of the Congo
Bandundu Hospital
Bandundu Province, Kwilu, Democratic Republic of the Congo
Masi Manimba Hospital
Masi-Manimba, Kwilu, Democratic Republic of the Congo
Nkara Secondary Hospital
Nkara, Kwilu, Democratic Republic of the Congo
Mushie Hospital
Mushie, Maï Ndombe Province, Democratic Republic of the Congo
Dubreka Hospital
Dubréka, Guinea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.